Will CME Group (CME) beat quarterly earnings?

“Record Q1 2026 volumes already publicly disclosed: 36.2M contracts ADV (+22% YoY) with simultaneous records across ALL SIX major asset classes for the first time in CME history — this directly drives ~80% of revenue (clearing/transaction fees).. March 2026 ADV hit 41.1M contracts (+33% YoY), a monthly record, indicating accelerating momentum into quarter-end rather than front-loaded volume..”

“The bull case leans heavily on trading volume, but EPS is not a linear function of headline ADV. CME's earnings depend on revenue capture per contract, product mix, incentive pricing, OTC/clearing economics, interest income, and expenses. Record contracts do not guarantee enough incremental EPS to clear a narrowly defined threshold.. There is an explicit data-quality problem in the bull research: it cites conflicting 'consensus' estimates for the same quarter ($3.11, $3.20, $3.23 market threshold, and $3.30). That does not prove a beat; it shows source inconsistency. For market resolution, only the contract's reference threshold matters. Using higher outside estimates to argue upside while also citing a lower 'consensus' is structurally sloppy and may reflect fabricated or mismatched snapshots..”